- Home
- BVN vs GRFS Comparison
BVN vs GRFS Comparison
Compare BVN & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BVN | GRFS |
|---|---|---|
| Founded | 1953 | 1940 |
| Country | Peru | Spain |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 6.2B |
| IPO Year | 1996 | 2006 |
Fundamental Metrics
Financial Performance| Metric | BVN | GRFS |
|---|---|---|
| Price | $34.32 | $8.81 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 2 |
| Target Price | ★ $27.00 | $10.15 |
| AVG Volume (30 Days) | ★ 1.9M | 442.6K |
| Earning Date | 02-19-2026 | 07-28-2022 |
| Dividend Yield | 0.85% | ★ 1.56% |
| EPS Growth | ★ 20.28 | N/A |
| EPS | ★ 1.70 | 0.64 |
| Revenue | $1,407,837,000.00 | ★ $8,821,017,248.00 |
| Revenue This Year | $30.26 | $5.36 |
| Revenue Next Year | $17.15 | $5.15 |
| P/E Ratio | $20.08 | ★ $17.98 |
| Revenue Growth | ★ 26.97 | 7.31 |
| 52 Week Low | $12.20 | $6.19 |
| 52 Week High | $34.51 | $11.14 |
Technical Indicators
Market Signals| Indicator | BVN | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 80.83 | 41.49 |
| Support Level | $29.18 | $9.17 |
| Resistance Level | $28.95 | $9.57 |
| Average True Range (ATR) | 1.00 | 0.22 |
| MACD | 0.43 | -0.03 |
| Stochastic Oscillator | 86.56 | 5.13 |
Price Performance
Historical ComparisonAbout BVN Buenaventura Mining Company Inc.
Compania de Minas Buenaventura SAA is a Peruvian precious metals-producing company with experience in mine exploration, development, construction, and operation.
About GRFS Grifols S.A.
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.